12 results on '"Hidechika Okada"'
Search Results
2. Neutrophil activation and arteritis induced by C. albicans water-soluble mannoprotein-β-glucan complex (CAWS)
- Author
-
Kei Takahashi, Shin Ichiro Kashiwamura, Haruki Okamura, Peter A. Ward, Akinori Okumura, Toshiaki Oharaseki, Hidechika Okada, Naohito Ohno, Kazuo Suzuki, Hitoshi Tachikawa, Akiko Ishida-Okawara, and Noriko Nagi-Miura
- Subjects
CAWS, C. albicans water-soluble mannoprotein-β-glucan complex ,fMLP, fMet-Leu-Phe ,Endothelium injury ,Male ,Chemokine ,medicine.medical_specialty ,beta-Glucans ,Endothelium ,medicine.medical_treatment ,Clinical Biochemistry ,Inflammation ,Granulocyte ,Article ,Neutrophil Activation ,Pathology and Forensic Medicine ,Proinflammatory cytokine ,Mice ,Internal medicine ,Candida albicans ,Granulocyte Colony-Stimulating Factor ,medicine ,Animals ,Arteritis ,Molecular Biology ,Membrane Glycoproteins ,biology ,business.industry ,Water ,Complement C3 ,medicine.disease ,Inflammatory cytokines ,Intercellular Adhesion Molecule-1 ,Coronary Vessels ,Complement system ,Complement activation ,Disease Models, Animal ,Cytokine ,medicine.anatomical_structure ,Endocrinology ,Solubility ,Immunology ,biology.protein ,Cytokines ,medicine.symptom ,business - Abstract
We have established a mouse model which shows the symptoms of coronary arteritis after consecutive injections of CAWS, which is released from Candida albicans. In this study, we examined neutrophil activation in the initial period after CAWS injection intraperitoneally. During 10 min to 16 h after the injection, blood profiles and neutrophil functions were determined. At the same time, levels of inflammatory cytokines and chemokines in plasma were measured. Furthermore, level of ICAM-1 as a marker of lesion in arterial endothelial cells was measured. Counts of the peripheral leukocytes increased immediately after CAWS injection, especially involving neutrophil. In vitro sensitivity of neutrophils to stimuli was enhanced. Moreover, proinflammatory cytokines (IL-1beta, IL-12 and IL-6) increased in plasma initially followed by an increase in IL-10, G-CSF, MIP-2 and soluble ICAM-1. Locally, ICAM-1 message in arterial walls was significantly increased 16 h after CAWS injection. A decrease in C3 levels was observed in plasma, suggesting complement activation and consumption. In summary, neutrophil activation occurred after CAWS injection, followed by complement activation, and production of proinflammatory cytokines chemokines and G-CSF which may be involved in development of coronary arteritis.
- Published
- 2007
3. Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal.
- Author
-
Daiki Iguchi, Masashi Mizuno, Yasuhiro Suzuki, Fumiko Sakata, Shoichi Maruyama, Alan Okada, Hidechika Okada, and Yasuhiko Ito
- Abstract
In a previous study of fungal peritoneal injury in peritoneal dialysis patients, complement (C)-dependent pathological changes were developed in zymosan (Zy)-induced peritonitis by peritoneal scraping. However, the injuries were limited to the parietal peritoneum and did not show any fibrous encapsulation of the visceral peritoneum, which differs from human encapsular peritoneal sclerosis (EPS). We investigated peritoneal injury in a rat model of Zy-induced peritonitis pretreated with methylglyoxal (MGO) instead of scraping (Zy/MGO peritonitis) to clarify the role of C in the process of fibrous encapsulation of the visceral peritoneum. Therapeutic effects of an anti-C5a complementary peptide, AcPepA, on peritonitis were also studied. In Zy/MGO peritonitis, peritoneal thickness, fibrin exudation, accumulation of inflammatory cells, and deposition of C3b and C5b-9 with loss of membrane C regulators were increased along the peritoneum until day 5. On day 14, fibrous encapsulation of the visceral peritoneum was observed, resembling human EPS. Peritoneal injuries and fibrous changes were significantly improved with AcPepA treatment, even when AcPepA was administered following injection of Zy in Zy/MGO peritonitis. The data show that C5a might play a role in the development of encapsulation-like changes in the visceral peritoneum in Zy/MGO peritonitis. AcPepA might have therapeutic effects in fungal infection-induced peritoneal injury by preventing subsequent development of peritoneal encapsulation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats
- Author
-
L Baranyi, Noriko Okada, Hidechika Okada, S Ichida, A Iguchi, H Takizawa, B P Morgan, and Seiichi Matsuo
- Subjects
Male ,Mean arterial pressure ,medicine.drug_class ,Immunology ,Vascular permeability ,Blood Pressure ,CD59 Antigens ,Receptors, Cell Surface ,Monoclonal antibody ,Capillary Permeability ,Mice ,In vivo ,Antigens, CD ,medicine ,Leukocytes ,Immunology and Allergy ,Animals ,Platelet ,Anaphylatoxin ,Rats, Wistar ,Complement Activation ,Elapid Venoms ,Mice, Inbred BALB C ,Membrane Glycoproteins ,biology ,Antibodies, Monoclonal ,Articles ,Complement C3 ,Molecular biology ,Complement system ,Rats ,Receptors, Complement ,Antigens, Surface ,biology.protein ,Receptors, Complement 3b ,Antibody - Abstract
The present work was designed to evaluate the effects of functional suppression of complement regulatory proteins in vivo. Male Wistar rats were anesthetized with Nembutal and were intravenously injected with 1 mg/kg of F(ab')2 or Fab fraction of either monoclonal antibody 5I2, which inhibits the function of rat counterpart of mouse Crry/p65, or monoclonal antibody 6D1, which inhibits the rat counterpart of CD59. Mean arterial pressure was continuously measured for 30 min. When 5I2 was injected, there was a biphasic change of mean arterial pressure, namely, the rapid increase immediately after the injection (approximately 2 min, phase 1) and the subsequent fall and slow recovery (approximately 4-30 min, phase 2). These effects were completely abrogated by pretreatment of rats with cobra venom factor. Pretreatment with carboxypeptidase inhibitor, which inhibits inactivation of anaphylatoxins C3a and C5a, induced enhanced reduction of blood pressure. Circulating leukocytes and platelets were rapidly decreased 5 min after antibody injection and became normal by 2 h. Hematocrit and erythrocyte count were continuously increased up to 2 h after injection, suggesting that there was hemoconcentration due to increased vascular permeability. Immunofluorescence study revealed binding of antibody fragments and rat C3 along the capillaries of lung, heart, and liver 5 min after injection. In contrast to 5I2, F(ab')2 fraction of 6D1, though localized to the same areas and in similar amounts, had no significant effect on the parameters measured. These data suggest that the rat counterpart of mouse Crry/p65 plays a vital role in vivo by preventing the activation of autologous complement on vascular endothelium.
- Published
- 1994
5. Tissue distribution of the guinea-pig decay-accelerating factor
- Author
-
Seiichi Matsuo, H Tamai, Noriko Okada, K Nishikawa, and Hidechika Okada
- Subjects
medicine.drug_class ,Immunology ,Guinea Pigs ,Urinary Bladder ,Fluorescent Antibody Technique ,Thymus Gland ,Biology ,Immunofluorescence ,Monoclonal antibody ,Kidney ,Guinea pig ,medicine ,Immunology and Allergy ,Animals ,Tissue Distribution ,Decay-accelerating factor ,Skin ,medicine.diagnostic_test ,Phospholipase C ,CD55 Antigens ,Myocardium ,fungi ,Ovary ,Synovial Membrane ,Uterus ,Brain ,Molecular biology ,Transmembrane protein ,Staining ,Capillaries ,medicine.anatomical_structure ,Liver ,Female ,Endothelium, Vascular ,Research Article - Abstract
MCA44 is a monoclonal antibody (mAb) to guinea-pig decay-accelerating factor (DAF) and, using this mAb, tissue distribution of guinea-pig DAF was studied by immunofluorescence. Guinea-pig DAF was found to be expressed not only on the vascular endothelium but also on different types of cells, such as the tubular epithelium of the kidney, epidermal cells of the skin and synovial lining cells. As there was no significant reduction in staining intensity with MCA44 following treatment with phosphatidylinositol-specific phospholipase C, many guinea-pig DAF molecules expressed in these tissues may be of the transmembrane form.
- Published
- 1998
6. Complement plays an essential role in shock following intestinal ischaemia in rats
- Author
-
Noriko Okada, M. Ikai, Y. Yokoyama, Hidechika Okada, Takashi Joh, and Makoto Itoh
- Subjects
Male ,Arginine ,Immunology ,Carboxypeptidases ,Biology ,Pathogenesis ,Rats, Sprague-Dawley ,Ischemia ,Mesenteric Vascular Occlusion ,medicine ,Immunology and Allergy ,Animals ,Anaphylatoxin ,3-Mercaptopropionic Acid ,Shock ,Original Articles ,Complement System Proteins ,Carboxypeptidase ,Complement system ,Rats ,Shock (circulatory) ,Reperfusion Injury ,biology.protein ,Lysine carboxypeptidase ,medicine.symptom ,Systemic shock - Abstract
Intestinal ischaemia lasting more than 30 min in rats causes fatal systemic shock. Systemic shock was suppressed by preadministration of cobra venom factor (CVF), which reduced the serum complement to less than 5% of the normal level, indicating that complement is involved in the syndrome. After complement activation, anaphylatoxins such as C3a and C5a are generated, and their activity is restricted by carboxypeptidases which remove C-terminal arginine from such bioactive peptides. As expected, preadministration of a carboxypeptidase inhibitor enhanced the systemic shock induced by the intestinal ischaemia. However, when the complement level was suppressed by CVF treatment, no fatal systemic shock was induced by the intestinal ischaemia even with preadministration of the carboxypeptidase inhibitor. These results indicate that complement plays a crucial role in systemic shock induced by intestinal ischaemia, and that anaphylatoxins generated by the complement activation should be involved in induction of the shock syndrome.
- Published
- 1996
7. Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study
- Author
-
Hidechika Okada, Kazuo Yoshioka, Noriko Okada, H Tamai, Atsushi Fukatsu, Kazuhiro Nishikawa, Nobuo Sakamoto, and Seiichi Matsuo
- Subjects
Pathology ,medicine.medical_specialty ,Immunology ,Kidney Glomerulus ,Lupus nephritis ,Fluorescent Antibody Technique ,CD59 Antigens ,Biology ,Immunofluorescence ,Peritubular capillaries ,Glomerulonephritis, Membranous ,Nephropathy ,Membranous nephropathy ,medicine ,Immunology and Allergy ,Humans ,Membrane Glycoproteins ,medicine.diagnostic_test ,urogenital system ,Complement C1q ,Nephrosis, Lipoid ,Fibrinogen ,Glomerulonephritis ,Complement C4 ,Glomerulonephritis, IGA ,Complement C3 ,medicine.disease ,Antigens, Differentiation ,Lupus Nephritis ,Staining ,Immunoglobulin A ,medicine.anatomical_structure ,Immunoglobulin M ,Immunoglobulin G ,Kidney Diseases ,Complement membrane attack complex ,Research Article - Abstract
SUMMARYThe 20-kD homologous restriction factor (HRF20), which is identical to CD59, is a membrane-associated protein which inhibits the reaction of C9 to form membrane attack complex (MAC) of homologous complements. In various human glomerular diseases deposition of complement components is frequently seen and MAC is reported to associate with immune deposits. Using a specific monoclonal antibody, 1F5, against HRF20, we attempted to study the localization of HRF20 in human glomerulonephritides and to compare the localization of HRF20 with those of immune deposits and MAC. The frozen sections of kidney specimens were fixed in acetone at room temperature before staining. In normal kidneys and kidney specimens from the patients with minimal change nephrotic syndrome, membranous nephropathy. and IgA nephropathy. HRF20 was strongly localized in the peritubular capillaries and along Bowman’s capsules. A weaker but well-defined staining was obtained in the mesangial area and faint staining was seen along the glomerular capillary walls. In contrast, glomerular capillary walls were rather strongly stained in the cases with diffuse lupus nephritis which had subendothelial dense deposits. These data suggest that HRF20 (CD59) is present in the human glomeruli and its expression is enhanced under certain conditions such as lupus nephritis.
- Published
- 1991
8. Anti-C5a complementary peptide ameliorates acute peritoneal injury induced by neutralization of Crry and CD59.
- Author
-
Tomohiro Mizuno, Masashi Mizuno, Masaki Imai, Yasuhiro Suzuki, Mayu Kushida, Yukihiro Noda, Shoichi Maruyama, Hidechika Okada, Noriko Okada, Seiichi Matsuo, and Yasuhiko Ito
- Subjects
PERITONEAL dialysis ,NEUTRALIZATION (Chemistry) ,CATHETERS ,PERITONITIS ,KIDNEY diseases ,TISSUES ,DISEASE complications - Abstract
In peritoneal dialysis (PD) therapy, physical stresses such as exposure to peritoneal dialysate, catheter trauma, and peritonitis may induce peritoneal injury that can prevent continued long-term PD therapy. Therefore, protection of the peritoneum is an important target to enable long-term PD therapy in patients with end-stage renal disease. We previously showed that neutralization of the membrane complement regulators (CRegs) Crry and CD59 in rat peritoneum provokes development of acute peritoneal injury due to uncontrolled complement activation. C5a is a key effecter molecule of the complement system released during acute inflammation. Control of C5a has been proposed as a strategy to suppress inflammatory reactions and, because peritoneal injury is accompanied by inflammation, we hypothesized that C5a targeted therapy might be an effective way to suppress peritoneal injury. In the present study we used an established acute peritonitis model induced by neutralization of CRegs to investigate the effects on acute peritoneal injury of inhibiting C5a. Intravenous administration of an anti-C5a complementary peptide (AcPepA) up to 4 h after induction of injury significantly and dose-dependently prevented accumulation of inflammatory cells and reduced tissue damage in the model, accompanied by decreased C3b deposition. We show that C5a contributed to the development of peritoneal injury. Our results suggest that C5a is a target for preventing or treating peritoneal injury in patients undergoing prolonged PD therapy or with infectious complications. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Complement C5a antagonism is associated with reduced big-endothelin level after experimental cardiac tamponade
- Author
-
András Mészáros, Noriko Okada, Hidechika Okada, Dániel Érces, Miklós Nógrády, Mihály Boros, József Kaszaki, Gabriella Varga, and Ildikó László
- Subjects
medicine.medical_specialty ,Biochemistry, Genetics and Molecular Biology(all) ,business.industry ,Complement C5a ,General Medicine ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,Pharmacology, Toxicology and Pharmaceutics(all) ,Internal medicine ,Anesthesia ,Cardiac tamponade ,medicine ,Cardiology ,Big endothelin 1 ,cardiovascular diseases ,General Pharmacology, Toxicology and Pharmaceutics ,Antagonism ,business ,circulatory and respiratory physiology - Full Text
- View/download PDF
10. Differing reactivities of human and guinea-pig complement on haptenized liposomes via the alternative pathway
- Author
-
Noriko Okada, Tatsuji Yasuda, Toru Tsumita, and Hidechika Okada
- Published
- 1983
- Full Text
- View/download PDF
11. Species-specific inhibition by gycophorin of complement activation via the alternative pathway
- Author
-
Hidechika, Okada and Hiroko, Tanaka
- Published
- 1983
- Full Text
- View/download PDF
12. Activation of the alternative complement pathway by IgM antibody reacted on paragloboside incorporated into liposome membrane
- Author
-
Hidechika, Okada, Noriko, Okada, and Tatsuji, Yasuda
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.